

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 July 2025 (10.07.2025)



(10) International Publication Number
WO 2025/147562 A9

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 25/28 (2006.01)
A61K 9/08 (2006.01) C07K 16/18 (2006.01)

Sweetwood Court, West Caldwell, NJ 07006 (US). **ZAGO, Wagner** [US/US]; 1291 Crestview Drive, San Carlos, CA 94070 (US).

(21) International Application Number:

PCT/US2025/010168

(74) Agent: **CONOUR, John, E.**; McDonnell Bochen Hulbert & Berghoff LLP, 300 South Wacker Drive, Chicago, IL 60606 (US).

(22) International Filing Date:

03 January 2025 (03.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/618,054 05 January 2024 (05.01.2024) US

(71) Applicant: **OTHAIR PROTHENA LIMITED** [IE/IE];
77 Sir John Rogerson's Quay, Block C, Grand Canal Dock-lands, Dublin 2, D02 VK60 (IE).


(72) Inventors; and

(71) Applicants: **CAMPBELL, Brian, Michael** [US/US]; 560 El Granada Boulevard, P.O. Box 2617, El Granada, CA 94018 (US). **SWANSON, Chad, James** [US/US]; 15

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

(54) Title: METHODS OF TREATING NEUROLOGICAL DISORDERS WITH ANTI-ABETA ANTIBODIES



(57) Abstract: Antibodies that bind human beta-amyloid, peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

28 August 2025 (28.08.2025)

(15) Information about Correction:

see Notice of 28 August 2025 (28.08.2025)